Identification of a Small-Molecule Inhibitor of DNA Topoisomerase II by Proteomic Profiling  by Kawatani, Makoto et al.
Chemistry & Biology
ArticleIdentification of a Small-Molecule Inhibitor
of DNA Topoisomerase II by Proteomic Profiling
Makoto Kawatani,1 Hiroshi Takayama,1,2 Makoto Muroi,1 Shinya Kimura,3 Taira Maekawa,4 and Hiroyuki Osada1,2,*
1Chemical Biology Core Facility, Chemical Biology Department, RIKEN Advanced Science Institute, Saitama 351-0198, Japan
2Graduate School of Science and Engineering, Saitama University, Saitama 338-8570, Japan
3Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan
4Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto 606-8507, Japan
*Correspondence: hisyo@riken.jp
DOI 10.1016/j.chembiol.2011.03.012SUMMARY
BNS-22, a chemically synthesized derivative of the
natural plant product GUT-70, has antiproliferative
activity against human cancer cells, the mechanism
of which is unknown. Here, we identify a target of
BNS-22 by proteomic profiling analysis, which
suggests that BNS-22 belongs to the same cluster
as ICRF-193, aDNA topoisomerase II (TOP2) catalytic
inhibitor. BNS-22 inhibits kinetoplast DNA decatena-
tion that is mediated by human TOP2a and TOP2b
in vitro at an IC50 of 2.8 and 0.42 mM, respectively.
BNS-22 does not affect DNA damage and antago-
nizes TOP2 poison-mediated DNA damage. Like
ICRF-193, BNS-22 induces mitotic abnormalities,
characterized by impairments in chromosome align-
ment and segregation, thereby causing polyploidy
in HeLa cells. These results indicate that BNS-22
targets TOP2 and acts as its catalytic inhibitor.
INTRODUCTION
The promising trends of anticancer drug development programs
that were initiated in the early postgenomic era have not trans-
lated into many clinical benefits. Researchers, however, have
learned much about the host- and cancer-related factors that
influence the prognosis of patients who are treated with drugs
that have well-defined molecular mechanisms of action. To
render a therapy more successful, at least one factor must be
elucidated—the precise mechanism of action.
Kimura et al. (2005) reported that the natural product GUT-70,
isolated from the stem bark of Calophyllum brasiliense in Brazil,
inhibits leukemic cell growth and induces caspase-mediated
apoptosis. These results prompted us to synthesize derivatives
of it that have more robust biological activity; of the more
than 60 derivatives of GUT-70, the compound BNS-22 fulfilled
this criterion. Yet, its molecular target and mechanism of action
remained unknown. A gradual and stepwise analysis of
a mechanism of action typically is a long-lasting process that
is accompanied by significant degree of uncertainty. Therefore,
the best and, hopefully, fastest such approach is a proteomic
analysis.Chemistry & Biology 18,Affinity purification of small-molecule binding proteins using
tagged probes, such as biotin conjugates and small-molecule
affinity matrices, is a commonly used method (Usui et al.,
2004; Teruya et al., 2005; Kawatani et al., 2008). Furthermore,
various multidimensional phenotypic profiling methods have
been reported to predict target proteins and mechanisms of
action of bioactive small molecules, including chemosensitivity
profiling of human cancer cell lines (Boyd et al., 2001; Yaguchi
et al., 2006), cell morphology–based profiling (Perlman et al.,
2004; Young et al., 2008), gene expression profiling (Gunther
et al., 2003; Lamb et al., 2006), and chemical proteomics
approaches (Bantscheff et al., 2007).
Recently, we reported a proteome-based profiling approach
to predict targets of bioactive small molecules using two-dimen-
sional fluorescence differential gel electrophoresis (2D-DIGE)
(Muroi et al., 2010). This method is based on recording the
comprehensive patterns of variation in proteins in HeLa cells
that are treated with small molecules. Our analysis revealed
that small molecules that share a molecular target, such as
Hsp90 inhibitors (geldanamycin and radicicol), V-ATPase inhibi-
tors (bafilomycin A1 and concanamycin A), and actin inhibitors
(cytochalasin D and jasplakinolide), can be grouped into the
same cluster. Thus, this proteomic approach is a powerful tool
that can be used to classify and predict targets of bioactive small
molecules.
Here, we identify a target molecule of BNS-22 by proteomic
profiling: DNA topoisomerase II (TOP2). TOP2 is an essential
nuclear enzyme that regulates DNA topology and many funda-
mental processes of DNA metabolism (Champoux, 2001;
Wang, 2002; Nitiss, 2009a). TOP2 creates a transient double-
strand break in one DNA molecule, through which a second
dsDNA molecule is transported (Wang, 2002; Nitiss, 2009a). In
mammals, there are two TOP2 isoforms, a and b, which share
70%sequence identity and have nearly identical catalytic prop-
erties in vitro (Austin and Marsh, 1998). They have distinct
patterns of expression and physiological functions inmammalian
cells (Isaacs et al., 1998). TOP2a expression is cell cycle regu-
lated, peaking in G2/M phase, and is essential for all cells. In
contrast, TOP2b expression is independent of the cell cycle and
occurs in proliferating and differentiated cells. TOP2b is required
for proper neural development in mice (Yang et al., 2000) but is
dispensable in other cell types. TOP2a has been proposed to
function in growth-dependent processes, such as DNA replica-
tion and chromosomal segregation, whereas TOP2b appears to
regulate transcription (Ju et al., 2006; Nitiss, 2009a).743–751, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 743
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Figure 1. BNS-22 Inhibits the Growth of HeLa Cells
(A) Structure of BNS-22.
(B) Effect of BNS-22 on HeLa cell growth. HeLa cells were treated with the
indicated concentrations of BNS-22 for 24 hr and 48 hr. Cell growth was
analyzed by WST-8 assay. Cell number (%) indicates the percentage of
control. Data are shown as the mean ± SD (n = 3).
See also Figure S1.
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Novel Small-Molecule TOP2 Catalytic InhibitorIn addition to its critical functions, TOP2 is a clinically impor-
tant target for cancer chemotherapy, and TOP2 inhibitors are
vital components in many therapeutic regimens (Nitiss, 2009b;
Pommier et al., 2010). TOP2-targeted inhibitors are classified
into two groups according to their mechanism of action: TOP2
poisons and catalytic inhibitors. TOP2 poisons, including
etoposide (VP-16), daunorubicin, mitoxantrone, and amsacrine,
stabilize the reversibly covalent TOP2-DNA complex—termed
the cleavable complex—that leads to DNA double-strand break
formation, resulting in cancer cell death (Wilstermann and
Osheroff, 2003). In contrast, TOP2 catalytic inhibitors block the
catalytic center of the enzyme without any association with the
formation of cleavable complexes or DNA breaks (Andoh and
Ishida, 1998; Larsen et al., 2003). Such agents include ICRF-
193 and the structurally related bisdioxopiperazine derivatives
(Tanabe et al., 1991), aclarubicin (Jensen et al., 1990), fostriecin,
merbarone, suramin, novobiocin, NSC35866 (Jensen et al.,
2005), and QAP 1 (Chene et al., 2009). ICRF-193, for example,
blocks the intrinsic ATPase activity of TOP2 and traps the
enzyme on DNA in its closed clamp form (Roca et al., 1994).
Our data indicate that the TOP2 is the target of BNS-22, as
predicted by proteomic profiling, and its mechanism of action
entails the inhibition of its catalytic center.
RESULTS
Proteomic Profiling of BNS-22-Treated HeLa Cells
BNS-22 (Figure 1A) inhibited the growth of the human cervix
epidermoid carcinoma cell line HeLa in a concentration-
dependent manner, as evidenced by the IC50 values of 4.9 and
1.0 mM for the 24- and 48-hr treatments, respectively (Figure 1B;
see Figure S1 available online). This result indicates that the
cytotoxic effects are time dependent, which is typical for
enzymatic inhibition rather than instantaneous and temporary
cellular damage.
To predict the mechanism of action of BNS-22, we performed
proteomic profiling of BNS-22–treated cells by 2D-DIGE. HeLa
cells were treated with 10 mMBNS-22 for 18 hr, and the resulting744 Chemistry & Biology 18, 743–751, June 24, 2011 ª2011 Elseviercell lysates were subjected to 2D-DIGE (Figures S2A and S2B).
The gel images were linked to our database, which contained
images that were generated by 42 well-characterized small
molecules. The 296 spots that matched on all gel images were
quantified using the 2D-DIGE system software, as described
elsewhere (Muroi et al., 2010). Then, hierarchical cluster analysis
was performed, and the results were displayed in a heatmap and
tree diagram. As shown in Figure 2, BNS-22 was clustered with
ICRF-193, a TOP2 catalytic inhibitor. In addition, our analysis
distinguished between the mechanisms of action of ICRF-193
and etoposide, a TOP2 poison (Figure 2). Our data predict that
BNS-22 targets TOP2 and acts as a TOP2 catalytic inhibitor,
not a TOP2 poison in cells. Aclarubicin, a known DNA-intercalat-
ing agent that prevents the binding of TOP2 to DNA rather than
inhibiting its activity, was not clustered with ICRF-193 (Figure 2).
This is probably because of the nonspecific effect of aclarubicin,
which is known to inhibit other proteins as well, such as TOP1
and the 20S proteasome (Figueiredo-Pereira et al., 1996; Larsen
et al., 2003).
BNS-22 PerturbsMitotic Spindle Formation and Induces
Polyploidy
Additional experiments were performed to determine the bio-
logical effect of BNS-22 on cell cycle in HeLa cells. By flow
cytometry, 24-hr treatment with BNS-22 increased the HeLa
cell population in G2/M phase in a concentration-dependent
manner (Figure 3A). However, exposure to 3 mM BNS-22
beyond 24 hr was accompanied by the presence of an 8C
peak (Figure 3B), characteristic of polyploidal cells. Similar
effects were observed in the human promyelocytic leukemia
cell line HL-60 (Figure S3).
Thus, we concluded that BNS-22 affects M phase events and
disturbs mitotic spindle formation. Moreover, by proteomic
profiling, BNS-22 was clustered near typical antimitotic agents,
such as vinblastine and nocodazole (Figure 2). To discriminate
the effects of these compounds, HeLa cells were exposed to 3
and 10 mM BNS-22, 10 mM ICRF-193, or 300 nM vinblastine for
12 hr and were stained with anti-b-tubulin, anti-g-tubulin, and
DAPI to visualize spindle and chromosomal morphology. ICRF-
193 and vinblastine were used as references to differentiate
the mechanisms of action. Vehicle-treated control cells and
BNS-22-treated cells did not differ morphologically during inter-
phase (Figure 3C), but during mitosis, the control cells harbored
a typical bipolar mitotic spindle, whereas BNS-22–treated cells
developed abnormal mitotic figures, characterized by unusually
distorted spindles and a failure of chromosomal alignment and
segregation (Figure 3C). Similar morphological changes were
induced by ICRF-193 (Figure S4A), a TOP2 reference compound
that was clustered with BNS-22 by proteomic profiling; vinblas-
tine, an antimicrotubular agent, effected dissimilar changes
(Figure S4B).
BNS-22 Inhibits TOP2 Activity
To confirmwhether BNS-22 inhibits TOP2 enzymatic activity, we
measured the effect of BNS-22 on TOP2-mediated kinetoplast
DNA decatenation. Kinetoplast DNA is a massive network that
consists of thousands of interlocked circular DNA molecules.
Because a transient double-strand break is necessary to release
circular DNA from the network, the decatenation of kinetoplastLtd All rights reserved
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Figure 2. Clustering of BNS-22 and 42 Well-Characterized Compounds by Proteomic Analysis of HeLa Cells
HeLa cells were treated with 10 mMBNS-22 for 18 hr. Proteome analysis was performed using 2D-DIGE. Quantitative data of the 296 spots were combined with
data on the 42 well-characterized compounds, and hierarchical clustering was performed. In the heat map, log-fold (natural base) of the normalized volume is
shown on the colored scale.
See also Figure S2 and Table S1.
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Novel Small-Molecule TOP2 Catalytic InhibitorDNA is believed to be a highly specific assay for TOP2 that cata-
lyzes double-strand passing. BNS-22, like ICRF-193, inhibited
kinetoplast DNA decatenation by human TOP2a and TOP2b
(Figures 4A and 4B). The mean IC50 value of BNS-22 for
TOP2a and TOP2b, obtained from three independent experi-
ments, was 2.8 ± 1.3 and 0.42 ± 0.09 mM, respectively, as deter-
mined by densitometric analysis.
We also observed the effect of BNS-22 on human DNA topo-
isomerase I (TOP1), which catalyzes topological changes in DNA
by transiently introducing single-strand breaks, to determine the
selectivity of BNS-22. A TOP1 inhibitor, camptothecin (100 mM),
which was used as a positive control, significantly inhibited
TOP1 activity, as measured by enzyme-mediated supercoiled
DNA relaxation, whereas BNS-22 had no effect at concentra-
tions up to 100 mM (Figure 4C).
BNS-22 Does Not Induce DNA Damage Associated
with DNA Double-Strand Breaks
TOP2 inhibitors are classified according to their ability to induce
DNA double-strand breaks due to the formation of cleavable
complexes (TOP2 poisons) or not (TOP2 catalytic inhibitors),
reflecting distinct mechanisms of inhibition. Moreover, TOP2
catalytic inhibitors antagonize TOP2 poison-mediated DNA
damage (Ishida et al., 1991; Tanabe et al., 1991). Our proteomic
profiling analysis suggested that BNS-22 acts as a TOP2Chemistry & Biology 18,catalytic inhibitor but not as a TOP2 poison (Figure 2). To confirm
this mode of inhibition, we examined the ability of BNS-22 to
induce DNA damage, as measured by histone H2AX phosphor-
ylation on serine 139, termed g-H2AX, a hallmark of DNA double-
strand breaks in cells (Rogakou et al., 1998). HeLa cells were
treated with 10 mM BNS-22, ICRF-193, or etoposide for 1 hr
and were stained with anti-g-H2AX. Etoposide induced the
robust formation of g-H2AX foci, in contrast to BNS-22 and
ICRF-193 (Figure 5A). To determine the antagonistic effects of
BNS-22 on etoposide-mediated DNA damage, HeLa cells were
pretreated with 10 mM BNS-22 or ICRF-193 for 30 min and
were treated with 10 or 30 mM etoposide for 1 hr. By western
blot, pretreatment with BNS-22 or ICRF-193 blocked etopo-
side-induced g-H2AX accumulation (Figure 5B), suggesting
that BNS-22 antagonizes TOP2 poison-mediated DNA damage.
TOP2b is preferentially degraded by the proteasome pathway
after cells are exposed to TOP2 poisons or catalytic inhibitors
(Mao et al., 2001; Xiao et al., 2003). We recapitulated these
effects in HeLa cells that were treated with BNS-22 or ICRF-
193; total cellular TOP2b levels declined markedly in a time-
and concentration-dependent manner, but TOP2a levels were
not significantly affected (Figures 5C and 5D). Considering the
predicted mode of action by proteomic profiling and these
results, we conclude that BNS-22 functions as a TOP2 catalytic
inhibitor.743–751, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 745
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Figure 3. BNS-22 Leads to Mitotic Perturbations
(A and B) Effect of BNS-22 on cell cycle. HeLa cells were treated with the indicated concentrations of BNS-22 for 24 hr (A) or with 3 mMBNS-22 for the indicated
times (B). Cells were fixed and analyzed by flow cytometry after propidium iodide staining.
(C) Effect of BNS-22 on mitotic spindle formation. HeLa cells were treated with 3 or 10 mM BNS-22 for 12 hr, fixed, and stained with anti-b-tubulin (green),
anti-g-tubulin (red), and DAPI (blue). Scale bar, 10 mm.
See also Figures S3 and S4.
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Novel Small-Molecule TOP2 Catalytic InhibitorTo examine whether BNS-22 could bind directly to TOP2,
we performed affinity precipitation assay using BNS-22–
immobilized beads. Purified human TOP2a coprecipitated with
BNS-22 beads, and competition was clearly observed in the
presence of BNS-22 but was absent with the addition of ICRF-
193 (Figure 5E). This result suggests that BNS-22 binds directly
to TOP2a in a different mode from ICRF-193.
Structure-Activity Relationship of BNS-22
Structural analogs of BNS-22 were synthesized and tested for
their ability to inhibit TOP2 activity (Table 1 and Figure S5). All
amides of the N-heterocyclic compound—BNS-51, BNS-52,
BNS-53, and BNS-54—failed to inhibit kinetoplast DNA decate-
nation by human TOP2a at concentrations up to 100 mM. The
inhibitory activity BNS-65, an ester of BNS-22, was 3-fold lower
than that of BNS-22. These results suggest that the 1,2,3,4-
tetrahydroquinoline structure of BNS-22 is essential for the inhi-
bition of TOP2 catalytic activity.
DISCUSSION
A new compound, BNS-22, was determined to possess signifi-
cant antiproliferative activity against several human cancer
cell lines, but its mode of action was unknown. To this end, by746 Chemistry & Biology 18, 743–751, June 24, 2011 ª2011 Elsevierproteomic profiling, we found that BNS-22 targets TOP2; in
contrast, its mother compound, GUT-70, a natural plant product
that has antileukemic activity (Kimura et al., 2005), does not
inhibit the DNA decatenation that is mediated by human
TOP2a up to 100 mM (Figure S5), indicating that GUT-70 and
BNS-22, despite having similar structures, have disparate
molecular targets.
Agents that target TOP2 are divided into two classes: TOP2
poisons, which stabilize DNA cleavable complexes and induce
DNA damage, and catalytic inhibitors, which interfere with
various steps in the catalytic cycle and inhibit growth by abolish-
ing the essential enzymatic activity of TOP2 (Larsen et al., 2003;
Wilstermann and Osheroff, 2003). Bisdioxopiperazines,
including ICRF-193, are believed to be specific TOP2 catalytic
inhibitors, in contrast to most other compounds that are claimed
to be catalytic inhibitors of TOP2. BNS-22 induces several
cellular phenotypes that are characteristic of bisdioxopipera-
zines in cells: First, BNS-22 does not induce DNA damage, as
evidenced by the lack of g-H2AX accumulation (Figure 5A),
and abrogates TOP2 poison-induced DNA damage (Figure 5B).
Second, BNS-22 preferentially degrades TOP2b; TOP2a is unaf-
fected (Figures 5C and 5D). Third, BNS-22 induces mitotic
abnormalities that are characterized by the inability of chromo-
somes to condense and segregate (Figure 3C; Figure S4A),Ltd All rights reserved
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Figure 4. BNS-22 Inhibits TOP2 Activity
(A and B) BNS-22 inhibits human TOP2-mediated kinetoplast DNA decate-
nation. Catenated kinetoplast DNA was incubated with human TOP2a (A) or
TOP2b (B) in the presence of the indicated compounds at 37C for 30min. DNA
samples were separated by electrophoresis on a 1% agarose gel. The posi-
tions of the catenated DNA (FI), decatenated products (FII), and linear DNA
(FIII) are indicated. Marker D, decatenated kinetoplast DNA; marker L, linear-
ized kinetoplast DNA; –, no human TOP2a (A) or TOP2b (B).
(C) BNS-22 does not inhibit human TOP1-mediated supercoiled DNA
relaxation. Supercoiled plasmid DNA was incubated with human TOP1 in the
presence of the indicated compounds at 37C for 30 min. DNA samples
were separated by electrophoresis on a 1% agarose gel. The positions of
nicked open circular DNA (FI), relaxed DNA (FII), and supercoiled DNA (FIII)
are indicated. M, relaxed plasmid DNA marker; –, no human TOP1; CPT,
camptothecin.
Chemistry & Biology
Novel Small-Molecule TOP2 Catalytic Inhibitorresulting in polyploidy (Figure 3B) (Muroi et al., 2010). Thus, these
findings strongly suggest that BNS-22 acts as a TOP2 catalytic
inhibitor in cells. Several reports suggest that bisdioxopipera-
zines can induce DNA damage in vitro, both in cell-free and in
intact cells, although this remains controversial (Huang et al.,
2001; Hajji et al., 2003; Jensen et al., 2004). The results of our
study clearly show that ICRF-193 and BNS-22 do not induce
DNA damage, thus contrasting the effects of the classical
TOP2 poison etoposide on cells (Figures 5A and 5B); therefore,
further studies are needed to evaluate the DNA-damaging
activity of BNS-22 and ICRF-193 under various experimental
conditions.
The inhibitory effects of BNS-22 against TOP2 are well docu-
mented, but several compounds possess dual modes of action
that allow them to inhibit both TOP1 and TOP2, such as the acri-
dine DACA, the benzopyridoindole intoplicine, the indenoquino-
linone TAS-103, the camptothecin analog BN 80927, and the
polysaccharide GA3P (Denny and Baguley, 2003; UmemuraChemistry & Biology 18,et al., 2003). TOP1-mediated supercoiled DNA relaxation was
not inhibited by BNS-22 at concentrations up to 100 mM (Fig-
ure 4C); thus, this newcompoundmust be classified as a specific
TOP2 inhibitor, acting by blocking catalytic activity.
The catalytic cycle of TOP2 can be parsed into six discrete
steps (Berger et al., 1996; Bates and Maxwell, 2007): (1) binding
of TOP2 to DNA, (2) double-stranded cleavage of the DNA, (3)
ATP-dependent DNA strand passage, (4) religation of the
cleaved DNA, (5) ATP hydrolysis, and (6) enzyme recycling.
Agents that inhibit TOP2 act through several mechanisms. For
example, aclarubicin blocks enzyme-DNA binding, the initial
step of the cycle (Sorensen et al., 1992), and merbarone blocks
DNA cleavage (Fortune and Osheroff, 1998). Bisdioxopipera-
zines inhibit the catalytic cycle of TOP2 by binding near the
ATP binding site and trapping the enzyme as a closed clamp
on DNA (Classen et al., 2003). Because the interaction between
TOP2a and BNS-22 was not inhibited by ICRF-193 (Figure 5E),
BNS-22may bind directly to TOP2 and inhibit its catalytic activity
differently from bisdioxopiperazines and, as a consequence,
may prevent TOP2 poison-induced DNA damage by stabilizing
TOP2-DNA complexes (Figure 5B). However, further investiga-
tion is needed to determine the precise mechanism by which
BNS-22 inhibits the catalytic activity of TOP2.
The identification of a mode of action is a crucial step during
drug development and is important in early preclinical studies,
when a substance is transferred from the in vitro to in vivo
evaluation stage. The lack of such knowledge can generate
disappointing results if a selected cancer does not express
a molecular target for an otherwise active compound. Under
such circumstances, a compound is judged to be inactive, and
in general, further evaluation is halted. Mindful of the possibility
for misjudgment, we developed a global system of classifying
chemical entities according to their presumably chief mecha-
nism of action, allowing us to make an informed selection of
the proper object of evaluation—a tumor. This system allowed
us to identify the probable mechanism of action of BNS-22
rapidly, which was confirmed in several steps. Our analysis re-
vealed that small molecules that share a target can be classified
by proteomics-based profiling (Muroi et al., 2010). With regard to
BNS-22, our cluster analysis distinguished between the mode of
action of ICRF-193 and etoposide, although they target the same
molecule, TOP2. Our data on BNS-22 demonstrate the effective-
ness of target prediction of small molecules by proteomics-
based profiling. At this stage, our tool does not need to identify
each spot, a generally time-consuming process in proteomic
analysis. Nevertheless, characterization of the spots that are
altered by treatment with small molecules might increase our
understanding of biological pathways and their responses to
small molecules. Expansion of the system, by increasing the
number of small molecules in the database and identifying spots,
will transform it into a more powerful and universal platform, not
only to identify mechanisms but also to demonstrate the proof of
concept of drugs that enter the clinical phase of evaluation.
TOP2 is an effective target against a wide range of malignan-
cies, andTOP2poisons, such as etoposide, doxorubicin, andmi-
toxantrone, have substantial clinical activity. Toxic side effects,
however, including drug-induced secondary malignancies,
have become a concern in TOP2 poison-based chemotherapy.
TOP2 catalytic inhibitors have not been explored extensively743–751, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 747
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Figure 5. Assessment of Relative Potency of TOP2 Catalytic Inhibitor
(A) BNS-22 does not induce DNA damage. HeLa cells were treated with 10 mM BNS-22, ICRF-193, or etoposide for 1 hr, fixed, and stained with anti-g-H2AX
(green) and DAPI (blue). Scale bar, 10 mm.
(B) BNS-22 antagonizes etoposide-induced DNA damage. HeLa cells were pretreated with 10 mM BNS-22 or ICRF-193 for 30 min and were treated with the
indicated concentrations of etoposide for 1 hr. Cell lysates were immunoblotted with anti-g-H2AX (top) and anti-a-tubulin (bottom).
(C and D) BNS-22 decreases TOP2b levels. HeLa cells were treated with 10 mM BNS-22 or ICRF-193 for the indicated times (C) or with the indicated concen-
trations of BNS-22 or ICRF-193 for 6 hr (D). Cell lysates were immunoblotted with anti-TOP2b (top) and anti-TOP2a (bottom).
(E) BNS-22 binds directly to TOP2a in a different mode than ICRF-193. Purified human TOP2a was incubated with control or BNS-22 beads in the presence or
absence of 100 mM BNS-22 or ICRF-193. The reactant beads were washed, and the eluted protein was immunoblotted with anti-TOP2a. C, control beads; B,
BNS-22 beads.
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Novel Small-Molecule TOP2 Catalytic Inhibitorin the clinical setting. For instance, bisdioxopiperazines were
developed originally as anticancer agents but have been used
principally as cardioprotecting agents in the clinic (Larsen et al.,
2003). ICRF-187 has clearly been shown toprevent cardiotoxicity
that is induced by doxorubicin and other anthracyclines; its ring-
opened hydrolysis product is claimed to act as a strong iron
chelator, diminishing the harmful effects of reactive oxygen
species on heart tissue. The clinical use as anticancer agents is
limited to MST-16 (Sobuzoxane), which is a prodrug of ICRF-
154. It is active against hematological malignancies but has
limited activity toward solid tumors (Larsen et al., 2003).
By definition, TOP2 poison-induced DNA damage can trigger
many DNA repair mechanisms; cells that initiate high levels of
such activity will resist these cytotoxic effects. Therefore,
cancers that lack this capacity are good targets for this treat-
ment. Conversely, TOP2 catalytic inhibitors that do not cause
DNA damage should be appropriate candidates for treating
cancers with fully active DNA repair systems, which mediate
clinical resistance to many anticancer agents. In addition, it is
unclear whether resistance to TOP2 poisons is associated with
the action of TOP2 catalytic inhibitors (Larsen and Skladanowski,
1998; Larsen et al., 2003). The clinical application of TOP2
catalytic inhibitors has expanded dramatically, according to
reports of the involvement of cancer-protective mechanisms in
instances of clinical failure. Thus, TOP2 catalytic inhibitors might748 Chemistry & Biology 18, 743–751, June 24, 2011 ª2011 Elsevierconstitute a second-line treatment in patients who no longer
respond to TOP2 poisons, cisplatin, and other agents.
In conclusion, we have demonstrated that BNS-22 targets
TOP2 and acts as its catalytic inhibitor in cells. Furthermore,
our study shows that proteomics-based profiling will aid in the
identification of mechanisms of action of bioactive small mole-
cules in future drug development and chemical genetic studies.
Although additional studies are needed, particularly with regard
to the molecular mechanism of inhibition by BNS-22 in the
catalytic cycle of TOP2 and its in vivo antitumor efficacy, BNS-
22 can be used to understand the biochemical and biological
functions of TOP2 and administered as an anticancer drug in
chemotherapy.
SIGNIFICANCE
Identifying the molecular target of uncharacterized bioac-
tive small molecules is a crucial step in drug development
and chemical genetic studies. Recent advances in omics
studies and multidimensional analyses have allowed us to
profile the effects of drugs by transcript analysis, proteo-
mics, cell phenotype assays, and chemosensitivity. In this
study, we identified the target of a small molecule, BNS-22,
which has antiproliferative activity against human cancer
cells, using our recently developed proteomic profilingLtd All rights reserved
Table 1. In vitro inhibition of TOP2 activity by BNS-22 derivatives
Compound BNS-22 BNS-51 BNS-52 BNS-53 BNS-54 BNS-65
Structure
O
OMe
MeO O
NO
O
OMe
MeO O
NO
O
OMe
MeO O
NO
O
OMe
MeO O
NO
O
OMe
MeO O
NO
O
OMe
MeO O
NO
OMe
O
IC50 (mM) 2.8 >100 >100 >100 >100 8.2
Catenated kinetoplast DNA was incubated with human TOP2a in the presence of the indicated compounds at 37C for 30 min. DNA samples were
separated by electrophoresis on a 1% agarose gel. The IC50 value was determined by densitometric analysis. See also Figures S1 and S5.
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a catalytic inhibitor in a cell system. TOP2, an essential
enzyme that regulates DNA topology, is a clinically impor-
tant target for cancer chemotherapy. Although various
TOP2 poisons, such as etoposide, have been used clinically,
the catalytic inhibition of TOP2 has not been explored exten-
sively in cancer treatment. Our study designates a structural
class of TOP2 inhibitors that can be used to treat cancers
that undergo high levels of DNA repair, compromising the
therapeutic effects of DNA-damaging agents.
EXPERIMENTAL PROCEDURES
Materials
The following materials were used: ICRF-193 (Funakoshi); camptothecin
(Calbiochem); etoposide, DAPI, anti-a-tubulin, anti-b-tubulin, and anti-
g-tubulin (Sigma-Aldrich); Alexa 488 donkey anti-mouse IgG and Alexa 568
goat anti-rabbit IgG (Molecular Probes); anti-TOP2a (MBL); anti-TOP2b (Santa
Cruz Biotechnology); anti-phospho histone H2AX (Ser139) (Upstate); purified
human TOP1 (Topogen), purified human TOP2a (Topogen or LAE Biotech
International); and purified human TOP2b (LAE Biotech International). The
synthesis of BNS-22 and its derivatives is described in Supplemental Experi-
mental Procedures and Figure S1. All compounds were dissolved in dimethyl-
sulfoxide (DMSO) as stock solutions, which were stored at 20C.
Cell Culture and Cell Growth Assay
The human cervix epidermoid carcinoma cell line HeLa (RIKEN Cell Bank)
was cultured in D-MEM (Invitrogen), supplemented with 10% fetal calf serum
(Invitrogen), 50 unit/ml penicillin (Invitrogen), and 50 mg/ml streptomycin
(Invitrogen), at 37C in a humidified atmosphere containing 5% CO2. HeLa
cells were seeded in a 96-well culture plate, cultured overnight, and exposed
to BNS-22 for the indicated times. After treatment, cell growth was measured
usingCell Count Reagent SF (Nacalai Tesque) according to themanufacturer’s
instruction. Briefly, 1/100 volume of the WST-8 solution was added to each
well, and the plates were incubated at 37C for 1 hr. Then, cell growth was
measured as the absorbance at 450 nm on a microplate reader (Perkin Elmer).
Proteome Analysis by 2D-DIGE
Proteome analysis by 2D-DIGE was performed as described elsewhere (Muroi
et al., 2010). Briefly, HeLa cells were treated with the designated concentra-
tions of BNS-22 or other inhibitors (Table S1) for 18 hr. Proteome analysis of
cell lysates was performed using a 2D-DIGE system (GE Healthcare), and
images of the gels were analyzed using Progenesis SameSpots (Nonlinear
Dynamics). Of the 298 spots that were described in a previous report, 296
spots were detectable in all gels (Muroi et al., 2010). The volume of each
spot was normalized using the average of the corresponding control values
from DMSO-treated HeLa cells, and hierarchical clustering analysis was
performed.Chemistry & Biology 18,Flow Cytometric Analysis
HeLa cells were seeded in a 6-well plate and exposed to BNS-22 for the indi-
cated times and concentrations. Cells were harvested, washed with PBS, and
fixed in 70% ethanol. Cells were washed twice with PBS again and incubated
with 50 mg/ml propidium iodide (Sigma-Aldrich) in PBS containing 2 mg/ml
RNase A (Nacalai Tesque) in the dark for 30 min. The DNA content of the cells
was analyzed on a Cytomics FC500 (Beckman Coulter).
Immunofluorescence Cell Staining
For b-tubulin and g-tubulin costaining, cells were cultured on glass coverslips,
fixed in methanol for 5 min, and washed with PBS. After blocking with 0.5%
BSA in PBS for 5 min at room temperature, the slides were incubated sequen-
tially with primary antibodies, each diluted 1:200 in PBS with 0.5% BSA, for
1 hr at 37C and with Alexa-conjugated secondary antibodies, each diluted
1:500 in PBS with 0.5% BSA, for 45 min at 37C.
For phospho-histone H2AX (Ser139) staining, cells that were cultured on
glass coverslips were fixed in 3.7% formaldehyde for 20 min, washed with
PBS, and permeabilized in 0.2% Triton X-100 in PBS for 5 min at room temper-
ature. After blocking with 0.5% BSA in PBS for 5 min at room temperature, the
slides were incubated sequentially with the primary antibody, diluted 1:200 in
PBS with 0.5% BSA, for 1 hr at 37C and with Alexa-conjugated secondary
antibody, diluted 1:500 in PBS with 0.5% BSA, for 45 min at 37C. DNA was
stained with 0.1 mg/ml DAPI in PBS. Images were analyzed on a fluorescence
microscope (PROVIS AX70, Olympus).
Kinetoplast DNA Decatenation Assay
TOP2 catalytic activity was measured, on the basis of ATP-dependent
decatenation of kinetoplast DNA, using the TOP2 assay kit (Topogen). The
reaction buffer, containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10 mM
MgCl2, 2 mM ATP, 0.5 mM DTT, and 30 mg/ml BSA for TOP2a, or 40 mM
Tris-HCl (pH 7.5), 100 mM KCl, 10 mM MgCl2, 2 mM ATP, 10 mM DTT,
0.5mMEDTA, and 30 mg/ml BSA for TOP2b, wasmixedwith 0.2 mg kinetoplast
DNA, 1 unit of human TOP2a or TOP2b, and the indicated concentrations of
the compounds in a total volume of 20 ml. After incubation at 37C for
30 min, the reaction was terminated with the addition of 4 ml stop solution.
The reaction mixtures were treated with 50 mg/ml proteinase K (Nacalai
Tesque) for 30 min at 37C to digest the protein. Samples were resolved by
electrophoresis on a 1% agarose gel containing 0.5 mg/ml ethidium bromide
in TAE buffer. DNA bands were visualized by UV exposure and photographed
on a UV transilluminator. Fluorescent bands were quantitated by scanning the
agarose gels on a Typhoon 9400 Variable Mode Imager (GE Healthcare).
Supercoiled DNA Relaxation Assay
TOP1 activity was measured, on the basis of the relaxation of supercoiled
DNA, using the TOP1 assay kit (Topogen). DNA relaxation assay was per-
formed according to the manufacturer’s instruction. Reaction buffer, contain-
ing 10 mM Tris-HCl (pH 7.9), 150 mM NaCl, 1 mM EDTA, 0.1% BSA, 0.1 mM
spermidine, and 5% glycerol, was mixed with 0.25 mg of supercoiled DNA,
4 units of human TOP1, and the indicated concentrations of the compounds
in a total volume of 20 ml. After incubation at 37C for 30 min, the reaction743–751, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 749
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treatedwith 50 mg/ml proteinase K for 30min at 37C to digest the protein. Two
microliters of loading buffer was added, and the DNA was extracted once with
CIA (chloroform:isoamyl alcohol, 24:1). Samples were resolved by electropho-
resis on a 1% agarose gel, after which the gel was stained with 0.5 mg/ml
ethidium bromide in TAE buffer for 30 min. DNA bands were visualized by
UV exposure and photographed on a UV transilluminator.
Western Blot
Western blot was performed as describedwith slight modifications (Woo et al.,
2006). Briefly, cell lysates were prepared in RIPA buffer (25 mM HEPES
[pH 7.8], 0.5 MNaCl, 5mMEDTA, 1.5% Triton X-100, 1.0% sodium deoxycho-
late, 0.1% SDS, and 5 mM EDTA), supplemented with a protease inhibitor
cocktail (Roche). Samples were subjected to SDS-PAGE and transferred to
a PVDF membrane (Immobilon P, Millipore). Membranes were incubated
with the indicated primary antibodies and horseradish peroxidase–labeled
secondary antibodies and visualized by exposure to X-ray film using SuperSig-
nal West Pico Chemiluminescence Substrate (Pierce).
BNS-22 Binding Assay
BNS-22–immobilized beads were prepared as described elsewhere (Kanoh
et al., 2005; Kawatani et al., 2008). Purified human TOP2a (500 ng) was incu-
bated with control or BNS-22 beads (20 ml) in the presence or absence of
100 mM BNS-22 or 100 mM ICRF-193 in binding buffer containing 40 mM
Tris-HCl (pH 7.5), 100 mM KCl, 10 mM MgCl2, 0.5 mM EDTA, 5 mM DTT,
2 mM ATP, and 0.1% BSA in a total volume of 1 ml for 3 hr at 4C. The reactant
beads were washed with binding buffer without BSA, and the bound protein
was eluted with SDS-PAGE sample buffer. The sample was resolved by
SDS-PAGE and detected by western blot with anti-TOP2a.
SUPPLEMENTAL INFORMATION
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